Sensor-augmented pump therapy at 36 months

Diabetes Technology and Therapeutics

Volumn 14, Issue 12, 2012, Pages 1174-1177

  Schmidt, Signe ^a   Norgaard, Kirsten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTIONS QUESTIONNAIRE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIA FEAR SURVEY; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROBLEM AREAS IN DIABETES QUESTIONNAIRE; PUMP DESIGN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSOR AUGMENTED PUMP; SHORT COURSE THERAPY;

ADULT; BIOSENSING TECHNIQUES; DENMARK; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84871001598     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0148     Document Type: Article

References (16)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
3. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476.
4. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311-320.
5. O'Connell MA, Donath S, O'Neal DN, Colman PG, Ambler GR, Jones TW, Davis EA, Cameron FJ: Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: A randomised controlled trial. Diabetologia 2009; 52:1250-1257.
6. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730-2732.
7. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M: Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The Real-Trend study. Diabetes Care 2009;32:2245-2250.
8. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA: Pensor-augmented insulin pump therapy: Results of the first randomized treat-to-target study. Diabetes Technol Ther 2008;10:377-383.
9. Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, Devries JH: Pensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med 2011;28:1158-1167.
10. Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378-1383.
11. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA: Pensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phase. Diabetes Care 2011;34:2403-2405.
12. Rubin RR, Peyrot M: Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. Diabetes Technol Ther 2012;14:143-151.
13. Schmidt S, Nørgaard K: Glucose sensor excludes hypoglycaemia as cause of death. Diabetes Res Clin Pract 2012; 96:e30Ye32.
14. Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, Chase HP, Hirsch I, Kollman C, Laffel L, Lawrence JM, Milaszewski K, Ruedy KJ, Tamborlane WV: Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care.2009;32:1947-1953.
15. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003;41: 582-592.
16. Schmidt S, Duun-Henriksen A, Nørgaard K: Psychosocial factors and adherence to continuous glucose monitoring in type 1 diabetes. J Diabetes Sci Technol 2012;986-987.